

Novugen Launched Sunitinib in the U.S. Market on 25th July 2024

We are excited to announce the U.S. market launch of Sunitinib 12.5mg, 25mg, 37.5mg, and 50mg, on 25th July 2024, following its ANDA approval in August 2023. This product is now being marketed by our colleagues at Novugen Pharma FE LLC (USA), including Victor Borelli and Michael Clark.



Sunitinib is a cancer treatment indicated for Gastrointestinal Stromal Tumors (GIST), Advanced Renal Cell Carcinoma (RCC), and Pancreatic Neuroendocrine Tumors (pNET).

This launch is a significant milestone for Novugen. We extend our deepest gratitude to our team for their unwavering dedication to making high-quality, life-changing medicines accessible to patients in the U.S. This achievement highlights our commitment to improving patient care and advancing cancer therapy worldwide.